Nodal signaling promotes a tumorigenic phenotype in human breast cancer

Seminars in Cancer Biology

Volumn 29, Issue C, 2014, Pages 40-50

  Kirsammer, Gina ^a   Strizzi, Luigi ^a,b   Margaryan, Naira V ^a   Gilgur, Alina ^a   Hyser, Matthew ^c   Atkinson, Janis ^c   Kirschmann, Dawn A ^a   Seftor, Elisabeth A ^a   Hendrix, Mary J C ^a,b  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c St Francis Hospital   (United States)

Author keywords

Breast cancer; C myc; ERK; Nodal; P27

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN NODAL; PROTEIN P27; RAS PROTEIN; CYCLINE; MYC PROTEIN, HUMAN; NODAL PROTEIN, HUMAN; ONCOFETAL ANTIGENS; P27 ANTIGEN; TUMOR ANTIGEN;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CARCINOGENICITY; CELL CYCLE ARREST; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; BIOSYNTHESIS; CELL TRANSFORMATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR INVASION;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; NODAL PROTEIN; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-MYC; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84927578186     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.07.007     Document Type: Review

References (27)

1. Shen M.M. Nodal signaling: developmental roles and regulation. Development 2007, 134(6):1023-1034.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988.
3. Charafe-Jauffet E., Monville F., Ginestier C., Dontu G., Birnbaum D., Wicha M.S. Cancer stem cells in breast: current opinion and future challenges. Pathobiology 2008, 75(2):75-84.
4. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11(3):259-273.
5. Strizzi L., Hardy K.M., Margaryan N.V., Hillman D.W., SEftor E.A., Chen B., et al. Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res. 2012, 14(3):R75.
6. Strizzi L., Postovit L.M., Margaryan N.V., Lipavsky A., Gadiot J., Blank C., et al. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol 2009, 4(1):67-78.
7. Lonardo E., Hermann P.C., Mueller M.T., Huber S., Balic A., Miranda-Lorenzo I., et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011, 9(5):433-446.
8. Lawrence M.G., Margaryan N.V., Loessner D., Collins A., Kerr K.M., Turner M., et al. Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate 2011, 71(11):1198-1209.
9. Postovit L.M., Margaryan N.V., Seftor E.A., Kirschmann D.A., Lipavsky A., Wheaton W.W., et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci USA 2008, 105(11):4329-4334.
10. Kossatz U., Dietrich N., Zender L., Buer J., Manns M.P., Malek N.P. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev 2004, 18(21):2602-2607.
11. Chu I.M., Hengst L., Slingerland J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008, 8(4):253-267.
12. Donovan J.C., Milic A., Slingerland J.M. Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 2001, 276(44):40888-40895.
13. Adhikary S., Eilers M. Transcriptional regulation and transformation by MYC proteins. Nat Rev Mol Cell Biol 2005, 6(8):635-645.
14. Chen C.R., Kang Y., Siegel P.M., Massague J. E2F4/5 and p107 as Smad cofactors linking the TGF beta receptor to c-myc repression. Cell 2002, 110(1):19-32.
15. Knoepfler P.S., Zhang X.Y., Cheng P.F., Gafken P.R., McMahon S.B., Eisenman R.N. Myc influences global chromatin structure. EMBO J 2006, 25(12):2723-2734.
16. Lin C.H., Lin C., Tanaka H., Fero M.L., Eisenman R.N. Gene regulation and epigenetic remodeling in murine embryonic stem cells by c-Myc. PLoS ONE 2009, 4(11).
17. Zhang X.Y., Varthi M., Sykes S.M., Phillips C., Warzecha C., Zhu W., et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 2008, 29(1):102-111.
18. Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149(2):307-321.
19. Vervoorts J., Luscher-Firzlaff J., Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 2006, 281(46):34725-34729.
20. Eisenman R.N. Deconstructing myc. Genes Dev 2001, 15(16):2023-2030.
21. Kerkhoff E., Houben R., Loffler S., Troppmair J., Lee J.E., Rapp U.R. Regulation of c-myc expression by Ras/Raf signalling. Oncogene 1998, 16(2):211-216.
22. Eckert L.B., Repasky G.A., Ulku A.S., McFall A., Zhou H., Sartor Cl, et al. Involvement of Ras activation in human breast cancer cell signaling: invasion, and anoikis. Cancer Res 2004, 64(13):4585-4592.
23. Nickeleit I., Zender S., Kossatz U., Malek N.P. p27kip1: a target for tumor therapies?. Cell Div 2007, 2:p13.
24. Padua D., Massague J. Roles of TGFbeta in metastasis. Cell Res 2009, 19(1):89-102.
25. Roarty K., Baxley S.E., Crowley M.R., Frost A.R., Serra R. Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype. Breast Cancer Res 2009, 11(2):R19.
26. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012, 13(10):616-630.
27. Quail D.F., Zhang G., Findlay S.D., Hess D.A., Postovit L.M. Nodal promotes invasive phenotypes via a mitogen-activated protein kinase-dependent pathway. Oncogene 2014; 2014, 33:461-473.